title: Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts.
abstract: The antitumor activity of spicamycin analogue SPM VIII against human stomach, breast, lung, colon and esophageal cancers was compared to that of mitomycin C (MMC) in the human tumor-nude mice xenograft model. Comparative studies of SPM VIII given i.v. at 6 mg/kg/day daily for 5 days and MMC given i.v. at 6.7 mg/kg on day 1 revealed that the antitumor spectrum of SPM VIII showed a different pattern from that of MMC and that SPM VIII caused tumor mass reductions in more tumors than did MMC in colon cancers (4/12 versus 1/11). In addition to this study, a comparative study of SPM VIII given i.v. at 12 mg/kg/day 8 times at 3- or 4-day intervals and 5'-deoxy-5-fluorouridine (5'-DFUR) given po at 185 mg/kg/day 5 days per week for 4 weeks showed that SPM VIII had the highest effect on SC-9 human stomach cancer and COL-1 human colon cancer among the 3 compounds, resulting in a significant reduction of tumor mass. Although other pharmacological studies are in progress, these results suggest that SPM VIII might be a novel antitumor compound effective for human cancers including cancer of the digestive organs.
authors.affiliation: Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Gunma, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kamishohara
authors.forename: H
authors.initials: H
authors.lastname: Kawai
authors.forename: A
authors.initials: A
authors.lastname: Odagawa
authors.forename: T
authors.initials: T
authors.lastname: Isoe
authors.forename: J
authors.initials: J
authors.lastname: Mochizuki
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: Y
authors.initials: Y
authors.lastname: Hayakawa
authors.forename: H
authors.initials: H
authors.lastname: Seto
authors.forename: T
authors.initials: T
authors.lastname: Tsuruo
authors.forename: N
authors.initials: N
authors.lastname: Otake
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D016685:Mitomycin / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D011684:Purine Nucleosides / Q000627:therapeutic use; D014183:Transplantation, Heterologous
chemical_list: D000903:Antibiotics, Antineoplastic; D011684:Purine Nucleosides; C091123:SPM VIII; D016685:Mitomycin; C015502:septacidin